Ads
related to: febuxostat when to take medication classification test for pneumonia patients
Search results
Results From The WOW.Com Content Network
Febuxostat, sold under the brand name Uloric among others, is a medication used long-term to treat gout due to high uric acid levels. [7] It is generally recommended only for people who cannot take allopurinol. [8] [9] It is taken by mouth. [7] Common side effects include liver problems, nausea, joint pain, and a rash. [7]
ATC code M04 Antigout preparations is a therapeutic subgroup of the Anatomical Therapeutic Chemical Classification System, a system of alphanumeric codes developed by the World Health Organization (WHO) for the classification of drugs and other medical products. [1] [2] [3] Subgroup M04 is part of the anatomical group M Musculo-skeletal system. [4]
Generally, drugs outlined within the ATC code M04 should be included in this category. Please see WP:PHARM:CAT for more information. Wikimedia Commons has media related to Antigout agents .
Necrotizing pneumonia (NP), also known as cavitary pneumonia or cavitatory necrosis, is a rare but severe complication of lung parenchymal infection. [ 5 ] [ 6 ] [ 7 ] In necrotizing pneumonia, there is a substantial liquefaction following death of the lung tissue, which may lead to gangrene formation in the lung.
Additional consideration is given to the treatment setting; most patients are cured by oral medication, while others must be hospitalized for intravenous therapy or intensive care. Current treatment guidelines recommend a beta-lactam, like amoxicillin, and a macrolide, like azithromycin or clarithromycin, or a quinolone , such as levofloxacin .
It is the most common bacterial pneumonia found in adults, the most common type of community-acquired pneumonia, and one of the common types of pneumococcal infection. The estimated number of Americans with pneumococcal pneumonia is 900,000 annually, with almost 400,000 cases hospitalized and fatalities accounting for 5-7% of these cases. [2]
A Risk Class III patient, after evaluation of other factors including home environment and follow-up, may either: [5] be sent home with oral antibiotics [4] be admitted for a short hospital stay with antibiotics and monitoring. [4] Patients with Risk Class IV-V pneumonia patient should be hospitalized for treatment. [4]
CURB-65, also known as the CURB criteria, is a clinical prediction rule that has been validated for predicting mortality in community-acquired pneumonia [1] and infection of any site. [2] The CURB-65 is based on the earlier CURB score [ 3 ] and is recommended by the British Thoracic Society for the assessment of severity of pneumonia. [ 4 ]